279 related articles for article (PubMed ID: 30498175)
21. The comparison of efficacy of adcortyl ointment and topical tacrolimus in treatment of erosive oral lichen planus.
Azizi A; Lawaf S
J Dent Res Dent Clin Dent Prospects; 2007; 1(3):99-102. PubMed ID: 23277842
[TBL] [Abstract][Full Text] [Related]
22. The onset risk of carcinoma in patients continuing tacrolimus topical treatment for oral lichen planus: a case report.
Morita M; Asoda S; Tsunoda K; Soma T; Nakagawa T; Shirakawa M; Shoji H; Yagishita H; Nishikawa T; Kawana H
Odontology; 2017 Apr; 105(2):262-266. PubMed ID: 27368962
[TBL] [Abstract][Full Text] [Related]
23. A study of prevalence of autoantibodies in patients with lichen planus from Mumbai, India.
Rambhia KD; Kharkar V; Pradhan V; Patwardhan M; Ghosh K; Khopkar US
Indian J Dermatol Venereol Leprol; 2018; 84(6):667-671. PubMed ID: 30058559
[TBL] [Abstract][Full Text] [Related]
24. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption.
Eming R; Rech J; Barth S; Kalden JR; Schuler G; Harrer T; Hertl M
Dermatology; 2006; 212(2):177-87. PubMed ID: 16484825
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy of tacrolimus 0.1% ointment and clobetasol propionate 0.05% ointment in oral lichen planus: a randomized double-blind trial.
Sonthalia S; Singal A
Int J Dermatol; 2012 Nov; 51(11):1371-8. PubMed ID: 23067089
[TBL] [Abstract][Full Text] [Related]
26. Anti-Desmoglein 1 and 3 Autoantibody Levels in Endemic Pemphigus Foliaceus and Pemphigus Vulgaris from Brazil.
Oliveira LA; Marquart-Filho A; Trevilato G; Timoteo RP; Mukai M; Roselino AM; Petzl-Erler ML
Clin Lab; 2016 Jul; 62(7):1209-1216. PubMed ID: 28164651
[TBL] [Abstract][Full Text] [Related]
27. Coexistence of IgA antibodies to desmogleins 1 and 3 in pemphigus vulgaris, pemphigus foliaceus and paraneoplastic pemphigus.
Mentink LF; de Jong MC; Kloosterhuis GJ; Zuiderveen J; Jonkman MF; Pas HH
Br J Dermatol; 2007 Apr; 156(4):635-41. PubMed ID: 17263817
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of severe recalcitrant erosive oral lichen planus with topical tacrolimus.
Shichinohe R; Shibaki A; Nishie W; Tateishi Y; Shimizu H
J Eur Acad Dermatol Venereol; 2006 Jan; 20(1):66-8. PubMed ID: 16405611
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of specific anti-desmoglein 1 and 3 enzyme-linked immunoassay and indirect immunofluorescence in the evaluation of pemphigus activity.
Barnadas MA; Rubiales MV; Gich I; Gelpí C
Int J Dermatol; 2015 Nov; 54(11):1261-8. PubMed ID: 25754029
[TBL] [Abstract][Full Text] [Related]
30. Topic tacrolimus, alternative treatment for oral erosive lichen planus resistant to steroids: a case report.
Riano Arguelles A; Martino Gorbea R; Iglesias Zamora ME; Garatea Crelgo J
Med Oral Patol Oral Cir Bucal; 2006 Nov; 11(6):E462-6. PubMed ID: 17072247
[TBL] [Abstract][Full Text] [Related]
31. Paraneoplastic pemphigus mimicking erosive mucosal lichen planus associated with primary hepatocellular carcinoma.
Yokokura H; Demitsu T; Kakurai M; Umemoto N; Azuma R; Yamada T; Suzuki M; Jimbu Y; Yoneda K; Ishii N; Hashimoto T
J Dermatol; 2006 Dec; 33(12):842-5. PubMed ID: 17169086
[TBL] [Abstract][Full Text] [Related]
32. The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels.
Harman KE; Seed PT; Gratian MJ; Bhogal BS; Challacombe SJ; Black MM
Br J Dermatol; 2001 Apr; 144(4):775-80. PubMed ID: 11298536
[TBL] [Abstract][Full Text] [Related]
33. Clinical and serological efficacy of topical calcineurin inhibitors in oral lichen planus: a prospective randomized controlled trial.
Vohra S; Singal A; Sharma SB
Int J Dermatol; 2016 Jan; 55(1):101-5. PubMed ID: 26147635
[TBL] [Abstract][Full Text] [Related]
34. Pimecrolimus vs. tacrolimus for the topical treatment of unresponsive oral erosive lichen planus: a 8 week randomized double-blind controlled study.
Arduino PG; Carbone M; Della Ferrera F; Elia A; Conrotto D; Gambino A; Comba A; Calogiuri PL; Broccoletti R
J Eur Acad Dermatol Venereol; 2014 Apr; 28(4):475-82. PubMed ID: 23451852
[TBL] [Abstract][Full Text] [Related]
35. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
Atzori L; Deidda S; Aste N
G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
[TBL] [Abstract][Full Text] [Related]
36. Effective treatment of erosive lichen planus with thalidomide and topical tacrolimus.
Petropoulou H; Kontochristopoulos G; Kalogirou O; Panteri I; Zakopoulou N
Int J Dermatol; 2006 Oct; 45(10):1244-5. PubMed ID: 17040454
[No Abstract] [Full Text] [Related]
37. Correlation of conventional and conformational anti-desmoglein antibodies with phenotypes and disease activities in patients with pemphigus vulgaris.
Li Z; Zhang J; Xu H; Jin P; Feng S; Wang B
Acta Derm Venereol; 2015 Apr; 95(4):462-5. PubMed ID: 25178305
[TBL] [Abstract][Full Text] [Related]
38. Analysis of immunological profile, clinical features and response to treatment in pemphigus.
Bardazzi F; Balestri R; Ismaili A; LA Placa M; Barisani A; Patrizi A
G Ital Dermatol Venereol; 2017 Dec; 152(6):569-577. PubMed ID: 27352177
[TBL] [Abstract][Full Text] [Related]
39. Detection of anti-desmoglein antibodies in oral lichen planus: What do we know so far.
Didona D; Hertl M
Front Immunol; 2022; 13():1001970. PubMed ID: 36263026
[TBL] [Abstract][Full Text] [Related]
40. Oral erosive lichen planus treated with efalizumab.
Cheng A; Mann C
Arch Dermatol; 2006 Jun; 142(6):680-2. PubMed ID: 16785369
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
